Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neurofibromatosis 1 2Ovarian Neoplasms 1Cognitive Dysfunction 1Chemotherapy-Related Cognitive Impairment 1Breast Neoplasms 1Attention Deficit Disorder with Hyperactivity 1

Interventions

AZD 6244 7trametinib 4mirdametinib 2fludarabine 2Inhalation 2Acetylcysteine 2thymoglobulin 1talimogene laherparepvec 1omipalisib 1lorlatinib 1fludarabine phosphate 1encorafenib 1dabrafenib 1binimetinib 1abemaciclib 1Vincristine 1Specimen Handling 1Sirolimus 1Rituximab 1Radiation 1N-monoacetylcystine 1Melphalan 1Magnetic Resonance Spectroscopy 1Levetiracetam 1Lasers, Solid-State 1Lasers 1Injections 1Deoxycholic Acid 1Cytarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neurofibromatosis 1 × Acetylcysteine × 90 days × Clear all
NCT04481048 2026-06-05

DoDNAC

Children's Hospital Medical Center, Cincinnati

Phase 2 Completed
25 enrolled 12 charts
CNS

Attention Deficit Disorder with Hyperactivity, Neurofibromatosis 1

NCT04481035 2026-04-21

NF1NAC

Children's Hospital Medical Center, Cincinnati

Phase 2 Completed
5 enrolled 10 charts
CNS

Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡